Impact of prophylactic systemic antibiotics (SA) on outcome of patients with RAS-wildtype (RAS-wt) metastatic colorectal carcinoma (mCRC) treated with cetuximab-based first-line therapy. Subgroup analysis of the German non-interventional study ERBITAG

Posted on by Silke Grassl
  • Autoren: S. Sahm, T.M.-O. Zahn, T. Goehler, M. Schwittay, J. Janssen, C.Hering-Schubert, K. Stenzel, and F. Overkamp
  • Institution: Ketteler Krankenhaus, Offenbach; Private Practice Goslar; Private Practice Onkozentrum Dresden; Private Practice, Groitzsch; Private Practice Westerstede; St. Georg Klinikum, Eisenach; Merck Serono GmbH, Darmstadt; Oncologianova, Recklinghausen
  • ESMO 2019 (Poster + Abstract)